R&D Network Meeting on Conjugated Antibodies

Oslo Cancer Cluster`s next member meeting will be an R&D Network Meeting on “Conjugated antibodies”. This will take place October 29th  at the Institute for Cancer Research, Oslo University Hospital. The R&D Network will focus on opportunities and challenges with conjugated antibodies, new treatment options and the clinical perspectives on the use of antibody-drug conjugates. […]

DNB invites to informal Healthcare gathering

You are invited to our informal gathering and DNB event for key personell in the Norwegian health care industry, 12th of November 2014. Please sign up by November 5th to https://www.deltager.no/DNBHealthcare_2014. Welcome to the DNB Healthcare event 12th of November in DNB’s Headquarter in Bjørvika, Dronning Eufemiasgt 30. Agenda 16:30-17:00 Registration and light food 17:00-17:10 […]

The Minister of Education pre launched the long-term plan for research and education with Lytix Biopharma

Yesterday Minister Røe Isaksen and the Minister of Health Bent Høie visited Lytix Biopharma at the Department of Cell therapy at the Cancer Research Institute/Oslo University Hospital. The background is that the Government will present a long-term plan for research and higher education on October 8. This white paper will outline how the government will […]

16 MNOK to BerGenBio from the Wellcome Trust

Oslo Cancer Cluster member BerGenBio AS has been granted a 1.6 million (NOK 16 million) Seeding Drug Discovery Award from the UK’s Wellcome Trust to develop novel small molecule inhibitors against BGB002, its proprietary, novel cancer target. The Wellcome Trust Seeding Drug Discovery Awards are to identify and fund especially promising, innovative new therapeutic concepts […]

Inven2 with broad immuno-oncology portfolio

Oslo Cancer Cluster member Inven2 is the largest technology transfer company in the Nordic region and a leading actor within Life Science. Oslo University Hospital and the University of Oslo are pioneers in several areas of immunology and cell based cancer therapies. Due to this, Inven2 has a broad portfolio within immuno-oncology to offer. Immuno-oncology […]